Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

  • ID: 4032606
  • Report
  • 483 pages
  • GlobalData
1 of 3
Non-Small Cell Lung Cancer (NSCLC) - 5EU Drug Forecast and Market Analysis to 2025

Summary

Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.

In 2015, the NSCLC market in the 5EU was an estimated $1.53B. This growth is fueled by the increasing use of immunotherapies across histologies and lines of therapy in NSCLC. Particularly, the use of PD-1 checkpoint inhibitors in first-line therapy of NSCLC is expected to take away significant sales from conventional chemotherapies that are typically used in the first line. Merck & Co.’s Keytruda is the current front-runner in the first-line setting, as it’s already approved as a monotherapy for =50% PD-L1+ patients, and is showing benefit in combination with chemotherapy regardless of PD-L1 expression.

Scope

- Overview of NSCLC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2015-2025.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU NSCLC market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for NSCLC.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2015-2025 in 5EU.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Related Reports

3 Disease Overview

3.1 Etiology and Pathophysiology

3.1.1 Etiology

3.1.2 Pathophysiology

3.2 Classification or Staging Systems

3.3 Symptoms

3.4 Prognosis

3.5 Quality of Life

4 Disease Management

4.1 Diagnosis and Treatment Overview

4.1.1 Diagnosis

4.1.2 Treatment Guidelines and Leading Prescribed Drugs

4.1.3 Clinical Practice

4.2 France

4.3 Germany

4.4 Italy

4.5 Spain

4.6 UK

5 Competitive Assessment

5.1 Overview

5.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting

5.2.1 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

5.2.2 Tarceva (erlotinib hydrochloride)

5.2.3 Iressa (gefitinib)

5.2.4 Gilotrif (afatinib)

5.2.5 Tagrisso (osimertinib)

5.2.6 Portrazza (necitumumab)

5.2.7 Conmana (icotinib)

5.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting

5.3.1 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors

5.3.2 Xalkori (crizotinib)

5.3.3 Zykadia (ceritinib)

5.3.4 Alecensa (alectinib)

5.4 Product Profiles - Major Brands, Monoclonal Antibodies

5.4.1 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors

5.4.2 Opdivo (nivolumab)

5.4.3 Keytruda (pembrolizumab)

5.4.4 Tecentriq (atezolizumab)

5.5 Product Profiles - Major Brands, Other

5.5.1 Avastin (bevacizumab)

5.5.2 Cyramza (ramucirumab)

5.5.3 Vargatef/Ofev (nintedanib)

5.6 Chemotherapies

6 Unmet Needs Assessment and Opportunity Analysis

6.1 Overview

6.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations

6.2.1 Unmet Need

6.2.2 Gap Analysis

6.2.3 Opportunity

6.3 Therapies Targeting Novel Biomarkers

6.3.1 Unmet Need

6.3.2 Gap Analysis

6.3.3 Opportunity

6.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting

6.4.1 Unmet Need

6.4.2 Gap Analysis

6.4.3 Opportunity

6.5 Alternative Testing Options for Patients with Insufficient Biopsy Material

6.5.1 Unmet Need

6.5.2 Gap Analysis

6.5.3 Opportunity

6.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance

6.6.1 Unmet Need

6.6.2 Gap Analysis

6.6.3 Opportunity

7 Pipeline Assessment

7.1 Overview

7.2 Promising Drugs in Clinical Development

7.2.1 Immune Checkpoint Inhibitors

7.2.2 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

7.2.3 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors

7.2.4 Therapeutic Cancer Vaccines

7.2.5 Anti-angiogenic Therapies

7.2.6 Avastin (bevacizumab) Biosimilars

7.2.7 KRAS Inhibitors

7.2.8 Tafinlar (dabrafenib) + Mekinist (trametinib)

7.2.9 Veliparib (ABT-888)

7.2.10 Seribantumab (MM-121)

7.2.11 IMMU-132 (sacituzumab govitecan)

7.2.12 Plinabulin (NPI-2358)

7.3 Promising Drugs in Early-Stage Development

7.3.1 Immune Checkpoint Inhibitors

7.3.2 Anaplastic Lymphoma Kinase Inhibitors

7.3.3 Neurotropic Tropomyosin-Related Kinase Inhibitors

7.3.4 MET inhibitors

7.3.5 Rearranged During Transfection Inhibitors

7.3.6 Human Epidermal Growth Factor 2 Inhibitors

7.3.7 PI3K Pathway Inhibitors

8 Market Outlook

8.1 5EU

8.1.1 Forecast

8.1.2 Key Events

8.1.3 Drivers and Barriers

9 Appendix

9.1 Bibliography

9.2 Abbreviations

9.3 Methodology

9.4 Forecasting Methodology

9.4.1 Diagnosed NSCLC Patients

9.4.2 Percent Drug-Treated Patients

9.4.3 Drugs Included in Each Therapeutic Class

9.4.4 Launch and Patent Expiry Dates

9.4.5 General Pricing Assumptions

9.4.6 Individual Drug Assumptions

9.4.7 Generic Erosion

9.4.8 Pricing of Pipeline Agents

9.5 Primary Research - KOLs

9.5.1 KOLs

9.6 About the Authors

9.6.1 Analyst

9.6.2 Therapy Area Director

9.6.3 Epidemiologist

9.6.4 Global Head of Healthcare

9.7 About the Author

9.8 Disclaimer

1.1 List of Tables

Table 1: Definitions Used in the AJCC Lung Cancer Staging System

Table 2: AJCC Staging of NSCLC

Table 3: Symptoms of NSCLC

Table 4: Prognostic Factors for NSCLC

Table 5: Prognosis for NSCLC Based on Initial Staging

Table 6: Prevalence of Brain and Bone Metastases in NSCLC

Table 7: Biomarker Testing Rates in Nonsquamous NSCLC

Table 8: Biomarker Testing Rates in Squamous NSCLC

Table 9: Treatment Guidelines for NSCLC

Table 10: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025

Table 11: Country Profile - France

Table 12: Country Profile - Germany

Table 13: Country Profile - Italy

Table 14: Country Profile - Spain

Table 15: Country Profile - UK

Table 16: Leading Treatments for NSCLC, 2016

Table 17: Marketed EGFR TKIs in NSCLC

Table 18: Product Profile - Tarceva

Table 19: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC

Table 20: Efficacy of Tarceva in Maintenance Therapy in NSCLC

Table 21: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC

Table 22: Safety of Tarceva

Table 23: Tarceva SWOT Analysis, 2016

Table 24: Product Profile - Iressa

Table 25: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)

Table 26: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)

Table 27: Safety of Iressa

Table 28: Iressa SWOT Analysis, 2016

Table 29: Product Profile - Gilotrif

Table 30: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC

Table 31: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC

Table 32: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC

Table 33: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC

Table 34: Safety of Gilotrif

Table 35: Gilotrif SWOT Analysis, 2016

Table 36: Product Profile - Tagrisso

Table 37: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC

Table 38: Safety of Tagrisso

Table 39: Tagrisso SWOT Analysis, 2016

Table 40: Product Profile - Portrazza

Table 41: Efficacy of Portrazza in First-Line, Squamous NSCLC

Table 42: Safety of Portrazza

Table 43: Portrazza SWOT Analysis, 2016

Table 44: Efficacy of Conmana in 2L Advanced NSCLC

Table 45: Efficacy of Conmana in 1L EGFR-mutant NSCLC

Table 46: Safety of Conmana

Table 47: Conmana SWOT Analysis, 2016

Table 48: Marketed ALK TKIs in NSCLC

Table 49: Product Profile - Xalkori

Table 50: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC

Table 51: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC

Table 52: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC

Table 53: Safety of Xalkori in Previously Treated, Metastatic NSCLC

Table 54: Xalkori SWOT Analysis, 2016

Table 55: Product Profile - Zykadia

Table 56: Efficacy of Zykadia

Table 57: Safety of Zykadia

Table 58: Zykadia SWOT Analysis, 2016

Table 59: Product Profile - Alecensa

Table 60: Efficacy of Alecensa

Table 61: Efficacy of Alecensa in NSCLC patients with CNS lesions

Table 62: Safety of Alecensa

Table 63: Alecensa SWOT Analysis, 2016

Table 64: Marketed PD-1/PD-L1 ICIs in NSCLC

Table 65: Product Profile - Opdivo

Table 66: Efficacy of Opdivo in Metastatic Squamous NSCLC

Table 67: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC

Table 68: Safety of Opdivo

Table 69: Opdivo SWOT Analysis, 2016

Table 70: Product Profile - Keytruda

Table 71: Efficacy of Keytruda

Table 72: Safety of Keytruda

Table 73: Keytruda SWOT Analysis, 2016

Table 74: Product Profile - Tecentriq (atezolizumab)

Table 75: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)

Table 76: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)

Table 77: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)

Table 78: Patient Demographics in the Phase II FIR Trial (NCT01846416)

Table 79: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)

Table 80: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)

Table 81: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)

Table 82: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)

Table 83: Tecentriq SWOT Analysis, 2016

Table 84: Product Profile - Avastin

Table 85: Efficacy of Avastin in Nonsquamous NSCLC

Table 86: Safety of Avastin

Table 87: Avastin SWOT Analysis, 2016

Table 88: Product Profile - Cyramza

Table 89: Efficacy of Cyramza

Table 90: Safety of Cyramza

Table 91: Cyramza SWOT Analysis, 2016

Table 92: Product Profile - Vargatef

Table 93: Efficacy of Vargatef in ADC NSCLC

Table 94: Safety of Vargatef in ADC NSCLC

Table 95: Vargatef SWOT Analysis, 2016

Table 96: Summary of Chemotherapies, 2015

Table 97: Unmet Need and Opportunity in NSCLC

Table 98: Product Profile - Yervoy (ipilimumab)

Table 99: Demographics in the Phase II NCT00527735 Trial

Table 100: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)

Table 101: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)

Table 102: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)

Table 103: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)

Table 104: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)

Table 105: Yervoy SWOT Analysis, 2016

Table 106: Product Profile - Avelumab (MSB-0010718C)

Table 107: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 108: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 109: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC

Table 110: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)

Table 111: Efficacy of Avelumab in Treatment-Naïve NSCLC

Table 112: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC

Table 113: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)

Table 114: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)

Table 115: Avelumab SWOT Analysis, 2016

Table 116: Product Profile - Durvalumab (MEDI4736)

Table 117: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial

Table 118: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial

Table 119: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II

Table 120: Efficacy of Durvalumab in Treatment-Naïve NSCLC

Table 121: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial

Table 122: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial

Table 123: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)

Table 124: Safety of Durvalumab in Treatment-Naïve NSCLC

Table 125: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial

Table 126: Durvalumab SWOT Analysis, 2016

Table 127: Product Profile - Naquotinib Mesylate (ASP8273)

Table 128: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials

Table 129: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients

Table 130: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients

Table 131: Naquotinib SWOT Analysis, 2016

Table 132: Product Profile - Olmutinib (BI 1482694; HM61713)

Table 133: Demographics in the Phase I/II NCT01588145 Trial

Table 134: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial

Table 135: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial

Table 136: Olmutinib SWOT Analysis, 2016

Table 137: Product Profile - Dacomitinib

Table 138: Demographics in the Phase II NCT00818441 Trial

Table 139: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial

Table 140: Safety of Dacomitinib in Phase II NCT00818441 Trial

Table 141: Dacomitinib SWOT Analysis, 2016

Table 142: Product Profile - Ensartinib

Table 143: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)

Table 144: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)

Table 145: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial

Table 146: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)

Table 147: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)

Table 148: Ensartinib SWOT Analysis, 2016

Table 149: Product Profile - Brigatinib

Table 150: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)

Table 151: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)

Table 152: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases

Table 153: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)

Table 154: Brigatinib SWOT Analysis, 2016

Table 155: Product Profile - CimaVax-EGF

Table 156: Demographics in the Phase III trial of the CimaVax-EGF in Cuba

Table 157: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba

Table 158: Safety of the CimaVax-EGF in the Phase III Trial in Cuba

Table 159: CimaVax-EGF SWOT Analysis, 2016

Table 160: Product Profile - Tedopi

Table 161: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC

Table 162: Efficacy of Tedopi in Advanced NSCLC

Table 163: Tedopi SWOT Analysis, 2016

Table 164: Product Profile - Anlotinib

Table 165: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial

Table 166: Anlotinib SWOT Analysis, 2016

Table 167: Product Profile - Aitan

Table 168: Efficacy of Aitan in Pretreated Nonsquamous NSCLC

Table 169: Aitan SWOT Analysis, 2016

Table 170: Product Profile - Fruquintinib

Table 171: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib

Table 172: Efficacy of Fruquintinib in Advanced Solid Tumors

Table 173: Safety of Fruquintinib in Advanced Solid Tumors

Table 174: Fruquintinib SWOT Analysis, 2016

Table 175: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)

Table 176: Product Profile - Abemaciclib

Table 177: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)

Table 178: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)

Table 179: Safety of Abemaciclib in Combination with Multiple Single Agents

Table 180: Abemaciclib SWOT Analysis, 2016

Table 181: Product Profile - Tafinlar + Mekinist

Table 182: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)

Table 183: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC

Table 184: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC

Table 185: Tafinlar + Mekinist SWOT Analysis, 2016

Table 186: Product Profile - Veliparib

Table 187: Demographics in the Phase II NCT01560104 Trial

Table 188: Efficacy of VCP in Advanced NSCLC (NCT01560104)

Table 189: Efficacy of VCP by Smoking Status (NCT01560104)

Table 190: Safety of VCP in Advanced NSCLC (NCT01560104)

Table 191: Veliparib SWOT Analysis, 2016

Table 192: Product Profile - Seribantumab (MM-121)

Table 193: Demographics in Group A of the Phase I/II Trial (NCT00994123) of MM-121 + Tarceva in

Table 194: Efficacy of MM-121 + Tarceva in EGFR Wild-Type NSCLC

Table 195: Safety of MM-121 + Tarceva in EGFR Wild-Type NSCLC

Table 196: MM-121 SWOT Analysis, 2016

Table 197: Product Profile - Sacituzumab govitecan (IMMU-132)

Table 198: Demographics in the Phase II Portion of the Phase I/II Trial (NCT01631552)

Table 199: Efficacy of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)

Table 200: Efficacy of IMMU-132 in Patients Who Progressed on Prior Checkpoint Inhibitor

Table 201: Safety of IMMU-132 in Pretreated NSCLC in the Phase I/II Trial (NCT01631552)

Table 202: IMMU-132 SWOT Analysis, 2016

Table 203: Product Profile - Plinabulin

Table 204: Efficacy of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)

Table 205: Safety of Plinabulin + Docetaxel in the Phase I/II Trial (NCT00630110)

Table 206: Plinabulin SWOT Analysis, 2016

Table 207: Early-Stage Clinical Development in NSCLC

Table 208: MET Status in the Phase II (NCT01610336) Trial

Table 209: Efficacy of Capmatinib + Iressa in MET+ NSCLC

Table 210: Demographics in the Phase II LURET Study

Table 211: Efficacy of Caprelsa in RET+ NSCLC

Table 212: Demographics in the Stage I of the Phase II NCT01639508 Trial

Table 213: Efficacy of Cometriq in RET+ NSCLC

Table 214: Key Events Impacting Sales for NSCLC in the 5EU, 2016

Table 215: NSCLC -Drivers and Barriers in the 5EU, 2015?2025

Table 216: Key Launch Dates - Part I

Table 217: Key Launch Dates - Part II

Table 218: Key Patent Expiries

Table 219 Average Body Weight and Surface Area Across the 8MM

Table 216: Average Cost of Therapy of Alimta in the 8MM

Table 217: Average Cost of Therapy of Alecensa in the 8MM

Table 218: Average Cost of Therapy of Avastin

Table 219: Average Cost of Therapy of Cyramza

Table 220: Average Cost of Therapy of Gilotrif

Table 221: Average Cost of Therapy of Iressa

Table 222: Average Cost of Therapy of Portrazza

Table 223: Average Cost of Therapy of Tagrisso

Table 224: Average Cost of Therapy of Tarceva

Table 225: Average Cost of Therapy of Vargatef

Table 226: Average Cost of Therapy of Xalkori

Table 227: Average Cost of Therapy of Zykadia

Table 228: Average Cost of Therapy of Keytruda

Table 229: Average Cost of Therapy of Opdivo

Table 230: Average Cost of Therapy of Tecentriq

Table 231: Average Cost of Therapy of Conmana

Table 232: High-Prescribing Physicians Surveyed by Country

1.2 List of Figures

Figure 1: Disease Management Flowchart for nonsquamous NSCLC

Figure 2: Disease Management Flowchart for squamous NSCLC

Figure 3: Disease Management Flowchart for EGFR+ NSCLC

Figure 4: Disease Management Flowchart for ALK+ NSCLC

Figure 5: Tarceva’s Phase III Development in NSCLC

Figure 6: Iressa’s Phase II Development in NSCLC

Figure 7: Gilotrif’s Phase III Development in NSCLC

Figure 8: Tagrisso’s Phase III Development in NSCLC

Figure 9: Portrazza’s Phase II Development in NSCLC

Figure 10: Conmana’s Phase III Development in NSCLC

Figure 11: Xalkori’s Development in NSCLC

Figure 12: Zykadia’s Development in NSCLC

Figure 13: Alecensa’s Development in NSCLC

Figure 14: Opdivo’s Development in NSCLC

Figure 15: Keytruda’s Phase III Development in NSCLC

Figure 16: Tecentriq’s Clincal Development in NSCLC

Figure 17: Avastin’s Phase III Development in NSCLC

Figure 18: Cyramza’s Phase III Development in NSCLC

Figure 19: Vargatef’s Phase II Development in NSCLC

Figure 20: NSCLC - Phase II/III Pipeline, 2016, Part I

Figure 21: NSCLC - Phase II/III Pipeline, 2016, Part II

Figure 22: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025

Figure 23: Yervoy’s Clinical Development in NSCLC

Figure 24: Clinical and Commercial Positioning of Yervoy

Figure 25: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025

Figure 26: Avelumab’s Development in NSCLC

Figure 27: Clinical and Commercial Positioning of Avelumab

Figure 28: Durvalumab’s Clinical Development in NSCLC

Figure 29: Clinical and Commercial Positioning of Durvalumab

Figure 30: Naquotinib’s Clincal Development in NSCLC

Figure 31: Clinical and Commercial Positioning of Naquotinib

Figure 32: Olmutinib’s Clincal Development in NSCLC

Figure 33: Clinical and Commercial Positioning of Olmutinib

Figure 34: Dacomitinib’s Clinical Development in NSCLC

Figure 35: Clinical and Commercial Positioning of Dacomitinib

Figure 36: Ensartinib’s Clinical Development in NSCLC

Figure 37: Clinical and Commercial Positioning of Ensartinib

Figure 38: Brigatinib’s Clinical Development in NSCLC

Figure 39: Clinical and Commercial Positioning of Brigatinib

Figure 40: CimaVax-EGF’s Clinical Development in NSCLC

Figure 41: Clinical and Commercial Positioning of CimaVax-EGF

Figure 42: Tedopi’s Clinical Development in NSCLC

Figure 43: Clinical and Commercial Positioning of Tedopi

Figure 44: Anlotinib’s Clinical Development in NSCLC

Figure 45: Clinical and Commercial Positioning of Anlotinib

Figure 46: Aitan’s Clinical Development in NSCLC

Figure 47: Clinical and Commercial Positioning of Aitan

Figure 48: Fruquintinib’s Clinical Development in NSCLC

Figure 49: Clinical and Commercial Positioning of Fruquintinib

Figure 50: Clinical Development of Avastin Biosimilars in NSCLC

Figure 51: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025

Figure 52: Abemaciclib’s Clinical Development in NSCLC

Figure 53: Clinical and Commercial Positioning of Abemaciclib

Figure 54: Tafinlar + Mekinist’s Clinical Development in NSCLC

Figure 55: Clinical and Commercial Positioning of Tafinlar + Mekinist

Figure 56: Veliparib’s Clinical Development in NSCLC

Figure 57: Clinical and Commercial Positioning of Veliparib

Figure 58: MM-121’s Clinical Development in NSCLC

Figure 59: Clinical and Commercial Positioning of MM-121

Figure 60: IMMU-132’s Clinical Development in NSCLC

Figure 61: Clinical and Commercial Positioning of IMMU-132

Figure 62: Plinabulin’s Clinical Development in NSCLC

Figure 63: Clinical and Commercial Positioning of Plinabulin

Figure 64: Sales for NSCLC in the 5EU by Drug Class, 2015-2025
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll